Advancing regulatory science in US FDA draft plan for 2011-2015
This article was originally published in SRA
A key area of focus for the US Food and Drug Administration in the near future will be to advance regulatory science in all aspects of its work, commissioner Margaret Hamburg has said in a draft report that lists the agency's strategic priorities for fiscal years 2011-151,2.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.